Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 8/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | ATIC | P31939 | 3/20 | 0.44 |
| ▸ | SGK1 | O00141 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968688 | 0.90 | MAP2K4 (0.57) | MAP2K4AURKASGK1MAP2K7BRD4 | |
| SCHEMBL3963379 | 0.89 | MAP2K4 (0.56) | MAP2K4AURKAATICSGK1CYP19A1 | |
| SCHEMBL3966208 | 0.88 | MAP2K4 (0.56) | MAP2K4AURKASGK1MAPK8MAPK10 | |
| SCHEMBL3969942 | 0.87 | MAP2K4 (0.54) | MAP2K4AURKASGK1CYP19A1MAPK8 | |
| SCHEMBL3967980 | 0.87 | MAP2K4 (0.62) | MAP2K4MAP2K7 | |
| SCHEMBL3971858 | 0.84 | MAP2K4 (0.56) | MAP2K4AURKACYP19A1MAP2K7BRD4 | |
| SCHEMBL3966924 | 0.84 | MAP2K4 (0.57) | MAP2K4AURKASGK1AVPR2GPR27 | |
| SCHEMBL3972614 | 0.84 | SLC22A12 (0.57) | SGK1 | |
| SCHEMBL3968449 | 0.83 | MEN1 (0.53) | MAP2K4AURKAMAP2K7 | |
| SCHEMBL3965414 | 0.83 | MAP2K4 (0.57) | MAP2K4AURKAMAPK8MAPK10MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K20 | MAP2K4 101/4885AURKA 2391/4885ATIC 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.